CIK 0001761612
- Non-accelerated filer
- Smaller reporting company
BICYCLE THERAPEUTICS PLC
Sign in to watch- Ticker
- BCYC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- Operating
- Phone
- +44 1223261503
- Business address
- BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
- Former names
- BICYCLE THERAPEUTICS Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $64,039
- in 7 filings, $7K under 10b5-1 plans
Net −$64,039. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Lee Kevin −$27K CHIEF EXECUTIVE OFFICER sold 1% of stake
- Swanton Robert Charles −$12K Director sold 18% of stake
- Skynner Michael −$9K CHIEF SCIENTIFIC OFFICER sold 2% of stake
- Perry Jennifer Scott −$7K Chief Operating Officer sold 2% of stake
- Hannay Michael Charles Ferguson −$6K CHIEF PROD & SUPPLY CHAIN OFF sold 2% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-14 | BINGHAM KATE Director | Sale | −43,378 | $34.01 | $1.5M | 1,831,671 |
| 2021-07-14 | BINGHAM KATE Director | Sale | −917 | $34.01 | $31K | 38,708 |
| 2021-07-14 | BINGHAM KATE Director | Sale | −43,378 | $34.01 | $1.5M | 1,831,671 |
| 2021-07-14 | BINGHAM KATE Director | Sale | −917 | $34.01 | $31K | 38,708 |
| 2021-07-13 | BINGHAM KATE Director | Sale | −588 | $33.50 | $20K | 1,875,049 |
| 2021-07-13 | BINGHAM KATE Director | Sale | −12 | $33.50 | $402 | 39,625 |
| 2021-07-13 | BINGHAM KATE Director | Sale | −588 | $33.50 | $20K | 1,875,049 |
| 2021-07-13 | BINGHAM KATE Director | Sale | −12 | $33.50 | $402 | 39,625 |
| 2021-01-04 | BINGHAM KATE Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2020-01-02 | BINGHAM KATE Director | Grant or award · Stock Option (right to buy) | +16,000 | 16,000 | ||
| 2019-05-28 | BINGHAM KATE Director | Conversion | +874,709 | 874,709 | ||
| 2019-05-28 | BINGHAM KATE Director | Conversion | +623,196 | 1,497,905 | ||
| 2019-05-28 | BINGHAM KATE Director | Conversion | +18,485 | 18,485 | ||
| 2019-05-28 | BINGHAM KATE Director | Conversion | +13,169 | 31,654 | ||
| 2019-05-28 | BINGHAM KATE Director | Purchase | +377,732 | $14.00 | $5.3M | 1,875,637 |
| 2019-05-28 | BINGHAM KATE Director | Purchase | +7,983 | $14.00 | $112K | 39,637 |
| 2019-05-28 | BINGHAM KATE Director | Conversion · Series A Preferred Shares | −874,709 | 0 | ||
| 2019-05-28 | BINGHAM KATE Director | Conversion · Series B1 Preferred Shares | −623,196 | 0 | ||
| 2019-05-28 | BINGHAM KATE Director | Conversion · Series A Preferred Shares | −18,485 | 0 | ||
| 2019-05-28 | BINGHAM KATE Director | Conversion · Series B1 Preferred Shares | −13,169 | 0 |
Page 1 of 1 · 20 trades